aTyr Pharma to Announce Second Quarter 2019 Results on August 14th

World News: . []

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2019 results after the market close on Wednesday, August 14, 2019. Management will host a conference call and webcast to review the results and provide a corporate update.

Domestic: (844) 358-9116

International: (209) 905-5951

Conference ID: 5599576

Webcast:

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. aTyr is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases. For more information, please visit .

Contact:

Joyce AllaireManaging Director, LifeSci Advisors, LLCallaire@lifesciadvisors.com

More news and information about aTyr Pharma, Inc.

Published By:

Globe Newswire: 13:00 GMT Wednesday 7th August 2019

Published: .

Search for other references to "atyr" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us